Eli Lilly requests for EUA approval from FDA for COVID-19 antibody
Category: #health  By Nikita Chaurasia  Date: 2020-10-09
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly requests for EUA approval from FDA for COVID-19 antibody

Eli Lilly and Company, the American pharmaceutical giant, has reportedly applied for emergency use authorization (EUA) for its potential COVID-19 antibody from the Food & Drug Administration (FDA). Sources with knowledge of the matter stated that the company has applied for EUA based on its previous study results and new information.

For those unfamiliar, Eli Lilly has developed a monoclonal antibody combination therapy called LY-CoV555 in order to treat the patients suffering from mild-to-moderate COVID-19. The company claims that its experimental antibody can help in reducing the virus level in the body as well as the overall hospitalization rates.

According to credible sources, the Phase 2 trials of the potential antibody comprised of around 112 people while up to 156 individuals were given a placebo. In this context, Eli Lilly specified that the patients who received the antibody therapy witnessed a significant decline in their virus levels after three to seven days.

Moreover, the company stated that over 0.9% of the patients on treatment went to emergency room or were hospitalized. Around 5.8% of the patients on placebo were apparently hospitalized as well.

Professor of pharmacoepidemiology at London School of Hygiene & Tropical Medicine, Stephen Evans was reported saying that although the data of phase 2 trials is encouraging, the experimental drug is still at preliminary stage. He further mentioned that the evidence derived from LY-CoV555 trials is not effective and needs to be studied more.

It is to be noted that Eli Lilly plans to produce over 1 million doses of its potential vaccine after receiving FDA authorization for its emergency use against the virus.

In other news, the FDA has reportedly informed the pharmaceutical companies to provide two months of safety data before authorizing the emergency use of their respective vaccines.

Source credits-

https://edition.cnn.com/2020/10/07/health/eli-lilly-antibody-therapy-results-eua/index.html

https://www.news18.com/news/world/u-s-fda-safety-guidelines-likely-to-push-covid-19-vaccine-authorization-past-election-2939275.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...